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ABSTRACT 
As technology and research evolve it is essential that practitioners in healthcare remain aware 
and cognizant of the changes that are going on around them and how these advancements may 
aid them in providing the best care to the patients that seek care from them. The largest 
breakthrough in the field of genetics has been the complete sequencing of the human genome. 
This landmark has paved the way for innumerable insights into every part of how care is 
delivered and stands to change the landscape of medicine entirely. Pharmacogenomics testing 
exists as a subset of genetic testing, and pertains to the evaluation of individual genetic variants 
that may interfere with the normal metabolism of many medications. There are specialty care 
settings where this modality of testing is more prevalent, but it is not well represented in primary 
care settings, where it stands to provide a wealth of information to primary care providers as they 
manage their patients. Literature review was conducted on this subject of interest and it was 
found that there was precedent for the implementation of pharmacogenomics testing in the 
primary care setting. Through survey of primary care providers, it was determined that there 
were deficits in knowledge and perspective barriers that were adequately addressed with an 
educational intervention. This intervention was shown to promote both the potential 
implementation of pharmacogenomics testing, generate interest in further education on the 
subject of pharmacogenomics, and address the identified perspective barriers.   
 Keywords:  Pharmacogenomics, pharmacogenomics cost-effectiveness, 
pharmacogenomics in primary care, implementation of pharmacogenomics  
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SECTION ONE: INTRODUCTION 
 
The field of pharmacogenomics is a branch of genetics testing that focuses on the way in 
which genetic variants affect the different aspects of drug metabolism, which can produce a 
continuum of negative effects in individuals that possess these variants who are taking these 
medications currently or may take them in the future. While this testing is widely available to be 
utilized in clinical practice there is not yet widespread adoption into clinical practice. 
Pharmacogenomics testing is a young field of research that has great promise for positively 
changing the way in which medicine is practiced in many ways. It holds the possibility of 
preventing potentially dangerous or life-threatening medication-related adverse events, promotes 
cost-effective care for patients, promotes increased patient agency in the care team, creates 
opportunity for deeper insight into effective management strategies for providers to utilize, 
promotes preventative versus reactive management of patients, and deepens the overall 
understanding of how vitally important the field of genetics is to the next steps of healthcare 
overall. 
While there is a large precedent and growing volume of knowledge regarding the benefits 
of utilizing pharmacogenomics testing in the clinical setting, there are well-studied barriers to the 
widespread adoption and implementation of this type of testing. There have been many 
advancements in the field of pharmacogenomics to address these various barriers, but the 
prevalence of this testing has remained low. There is little evidence on the subject of the effects 
of a targeted educational intervention that addresses the most common themes that stand as 
barriers to the implementation and adoption of pharmacogenomics in the primary care setting. 
The effects of a targeted educational intervention that addresses these barriers needs to be 
understood for conclusions to be drawn regarding approaches to these barriers in future research 
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and implementation projects. Therefore, a quasi-experimental study was conducted to determine 
the effects of a synthesized educational intervention regarding pharmacogenomics on primary 
care providers through comparative analysis of differences between pre and post surveys that 
evaluate the perspectives and level of understanding in these providers.   
Background 
 
There have been approximately 20 genes that have been evaluated to affect a vast amount 
of prescription medications to varying levels of degree. This type of testing focuses on the 
identification of genetic variation that affects different aspects of drug metabolism, absorption, 
distribution, and elimination. There are also genetic variances known to affect 
pharmacodynamics, which disturbs the biological pathways and can represent why patients may 
have stronger side effects from certain therapies. Initially, the clinical utilization of 
pharmacogenomics testing was through the deployment of monogenic testing on a reactive basis 
such as the prescription of pharmacogenetically high-risk drugs. This has, however, proved to be 
ineffective and costly, especially in light of advancements in sequencing technology that has 
allowed for multiple gene variants to be interrogated simultaneously. There are many potential 
cases where multiple genetic variants need to be assessed to understand patients’ risk of adverse 
outcomes, and because of this the standard has been shifted towards the standardized testing for 
many polymorphisms simultaneously to generate the largest amount of actionable data for care 
to be correctly guided (Relling & Evans, 2017). 
 Historically there have been many noted barriers to the translation of research into 
clinical practice for pharmacogenomics testing. There is a lack of incentive for clinicians to order 
testing for their patients to prevent adverse events, lack of knowledge regarding the use and 
interpretation of this testing, lack of clear and definable clinical guidelines that creates actionable 
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recommendations for the provider to change therapy, lack of formal education implemented in 
educational curriculum, and lack of laboratories that provide this service, which can be 
attributed, in part, to the relatively young field of pharmacogenomics testing (Relling & Evans, 
2017). 
 Adherence to prescribed pharmacotherapies is a prevalent problem in any setting, and a 
recent study at the Mayo Clinic found that 91% of the 1,010 participants reported that they 
would be more likely to use medications as they are prescribed if the medications were chosen 
through pharmacogenomics testing (Olson et al., 2017). Clinical validity and utility for 
pharmacogenomics testing has also been validated through the positive effects that have been 
evaluated through the ability to predict non-efficacious treatments, as well as providing effective 
predictions that improve clinical outcomes (Benitez, Jablonski, Allen, & Winner, 2015). These 
clinical outcomes include previously mentioned possible improvements in medication adherence 
along with reductions in rates of polypharmacy and avoidance of adverse reactions to 
medications. The avoidance of adverse drug reactions categorically has the potential for some of 
greatest impact on clinical validity and utility in pharmacogenomics testing, which has the 
capacity to comprehensively and accurately assess this type of risk in patients who receive this 
testing (Phillips, Veenstra, Oren, Lee, & Sadee, 2001). 
 One of the strongest established barriers regarding the implementation of 
pharmacogenomics testing in the clinical setting has been the economic implications of this 
testing and the unclear return on investment with this new means of insight (Wong, Carlson, 
Thariani, & Veenstra, 2010). Contributing to this issue is the lack of significant insights into the 
clinical utility and validity of this new testing tool, which is inevitably complicated by the lack of 
widespread implementation, study, and adherence to recommendations that are based  on testing 
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itself (Berm et al., 2016; Sauver et al., 2016). However, there have been helpful breakthroughs 
on this discussion of economic utility in the implementation of pharmacogenomics testing that 
stand to address this issue thoroughly. Berm et al. (2016) found through systematic review of 80 
previous studies centered around the cost-effectiveness of pharmacogenomics testing that there 
was substantial evidence in the majority of evaluated studies that this was not only cost effective 
but also promoted better clinical outcomes. This review was based on previous evidence that 
supported the cost effectiveness of pharmacogenomics testing, but did find inconclusive data 
regarding the clinical utility and validity of testing in some of the evaluated studies (Wong, 
Carlson, Thariani, & Veenstra, 2010). In another systematic review it was found that there was 
strong evidence for the utilization of pharmacogenomics testing towards the goal of preventing 
adverse drug reactions for specific pharmacotherapies (Pumpton, Roberts, Pirmohamed, & 
Hughes, 2016). It was established in all of these reviews that a limitation of the results that were 
evaluated was the absolute dependence on comprehensive and accurately reported data from 
implementation projects on which the outcomes of cost-effectiveness, clinical validity, and 
improvement in clinical outcomes was based (Berm et al., 2016; Pumpton, Roberts, 
Pirmohamed, & Hughes, 2016; Wong, Carlson, Thariani, & Veenstra, 2010). 
 These findings are the basis for an educational intervention being targeted towards 
addressing the knowledge base as well as the perspectives of providers in the clinical 
environment. Sauver et al. (2016) highlighted the complications of poor understanding and false 
perspectives regarding pharmacogenomics, with 52% of clinicians not understanding how to 
incorporate pharmacogenomics into their future practice along with not expecting this 
incorporation to take place at all. Additionally, it was found that 53% of the surveyed clinicians 
had very poor responses to the clinical decision tools set in place to alert them of possible 
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changes in management, and only 30% of the surveyed clinicians changed their 
pharmacotherapy to a different agent based on the recommendations supplied by 
pharmacogenomics testing (Sauver et al., 2016). Potential clarification for these findings was 
provided through the surveying of healthcare professionals in a different context, which revealed 
that while a vast majority of the participants believed that pharmacogenomics was relevant to 
their clinical practice, there were very few cases of personal implementation of this testing due to 
variables such as interpretation of testing results and knowledge regarding basic principles of 
pharmacogenomics (Just et al., 2017).  
 Due to these factors and variables it has been established that the phenomenon of interest 
relating to pharmacogenomics testing include the barriers of poor understanding and negative 
perspectives from providers who can provide the testing. There have been initiatives regarding 
pharmacogenomics education that have proven to be innovative in their approach and effective at 
promoting an enhanced understanding of pharmacogenomics testing (Adams et al., 2016). To 
understand the efficacy of pharmacogenomics testing and how to best implement this new 
management tool into clinical practice the barriers that exist need to be investigated and 
addressed comprehensively.   
Problem Statement 
 
There is a vast amount of evidence that exists to support the widespread implementation 
of pharmacogenomics testing in regular evaluation and management of patients seeking primary 
care, as there are many known and potential benefits through the use of this testing. The barriers 
that stand in the way of appropriate translation of research into clinical practice need to be 
evaluated thoroughly to appropriately address these variables and implement pharmacogenomics 
testing effectively in the primary care setting. There is evidence in the literature regarding the 
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barriers that exist, but insight needs to be drawn from these findings to create an intervention that 
should then be validated and refined through further research and implementation.  
Purpose of the Project 
 
 The purpose of this project is to evaluate the impact of a targeted educational intervention 
on a population of primary care providers’ perspectives and levels of understanding. This will be 
accomplished through establishing the barriers that are found in the literature that historically 
stand against the implementation of pharmacogenomics testing, and comparing these findings 
with the specific barriers that are found within the population of interest by means of surveying. 
These survey results will be combined with what is known in the literature to provide a targeted 
educational intervention that is comprehensive while being contextual to the specific needs of the 
population being studied. The project’s primary objective is to evaluate the efficacy of a targeted 
educational intervention at addressing the barriers to implementation of pharmacogenomics 
testing in clinical practice.  
Clinical Question 
 
 How does a targeted educational intervention affect the reported level of understanding 
and perspectives for providers in a primary care setting?  
SECTION TWO: LITERATURE REVIEW 
Search Strategy 
 
Systematic search through the literature for original research regarding the subject of 
pharmacogenomics was conducted. The evaluated databases included ProQuest, ScienceDirect, 
Public Library of Science, ClinicalKey, SpringerLink, and JAMA Network. The search terms 
used to procure evidence included “pharmacogenomics”, “pharmacogenomics cost-
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effectiveness”, “pharmacogenomics in primary care”, “pharmacogenomics in primary care”, and 
“implementation of pharmacogenomics”. Filters utilized for the review of relevant material 
included articles that were published in the English language within the last 10 years. Articles 
older than 10 years were not included due to the lack of relevance to the subject of 
pharmacogenomics presently. One article that does not meet the aforementioned filters was 
included for deeper background and historical context regarding the subject matter. A total of 37 
studies were found and of these 15 were kept for final review. The studies that were kept for 
inclusion were those that had relevance to the variables that stand as barriers to the 
implementation of pharmacogenomics, which are being assessed in this project. The studies 
included in this literature review discuss main points of interest in the themes identified as being 
important in the evaluation of pharmacogenomics testing. 
The studies included in the literature review contained several systematic reviews, which 
contributed to important conclusions regarding the variables of cost-effectiveness of 
pharmacogenomics testing in clinical use, as well as the clinical validity and utility of this testing 
(Berm et al., 2016; Pumpton et al., 2016; Wong et al., 2010). In addition to the literature 
providing insight into the cost-effectiveness of pharmacogenomics testing, there was also a 
systematic review that demonstrated the worth of pharmacogenomics testing to provide better 
clinical outcomes and prevent adverse drug reactions in patients receiving pharmacotherapies 
(Phillips, Veenstra, Oren, Lee, & Sadee, 2001). There was also a single correlational design 
study that was included to identify specific and practical findings regarding the cost-savings that 
are seen with patients undergoing pharmacogenomics testing (Brown, Lorenz, Li, & Dechario, 
2017). There were several articles included that had descriptive designs to provide support for 
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the notion of deficient provider knowledge base of pharmacogenomics testing (Relling & Evans, 
2015; Rosenman et al., 2017; Sauver et al., 2016).   
Critical Appraisal 
 
The overall body of evidence that was found through the review of literature shows 
support for the project’s interests and the variables that are to be addressed with the intervention 
included. Systematic reviews that were included in the literature review were evaluated using the 
CASP (2018) appraisal tool, which revealed that the results were valid and showed strong 
support for the results and conclusions that were drawn in these reviews. According to the CASP 
appraisal tool, the only point in which the systematic reviews were deficient was the uncertainty 
regarding the results being directly applicable to the contextual circumstances of this project’s 
focus.  
Important conclusions that were found through the review of literature should be 
scrutinized for potential bias and inability to generalize results. Examples of this include the 
findings of Sauver et al. (2016), which showed that there was a large percentage of surveyed 
clinicians who did not find the direct application of pharmacogenomics in their practice and had 
only changed practice due to pharmacogenomics results on very few occasions. There may be 
variables that are not obvious that can account for these findings, such as poor implementation 
plan of pharmacogenomics testing that did not include adequate education regarding the subject 
of pharmacogenomics, lack of clinical support in the implementation of this testing, age of the 
clinicians, previous experience with pharmacogenomics testing, or lack of clinician input into the 
clinical support tools that were utilized as part of this study by Sauver et al. (2016). Rosenman et 
al. (2017) found that the implementation of pharmacogenomics testing in their setting required 
leveraging key stakeholders in both hospital administration as well as clinicians who were 
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experts in this field to educate and assist other clinicians in the use and interpretation of 
pharmacogenomics testing. Beyond this, there was also discussion regarding the type of 
education that clinicians received, the frequency that this training was reinforced, and the support 
systems that were established to promote this change. If these variables were present in the 
previously mentioned study, it may have affected dramatic changes on the outcomes that were 
listed.  
Similarly, the findings of Just et al. (2017) can be negatively affected by bias that was not 
reported or controlled for in the study. The characteristics of the surveyed population were not 
explained thoroughly, which may have represented several issues of bias or inexperience that 
cannot be accounted for otherwise. Berm et al. (2016) explained some conflicting results in the 
systematic review of literature on the subject of economic utility of pharmacogenomics testing. 
Within the article it was explained that the conflicting results were due to the inadequate 
reporting of results in evaluated studies or the ineffective implementation of pharmacogenomics 
testing in the clinical setting, which promotes poor provider adherence to recommendations and 
subsequent misrepresentation in the data.   
Synthesis 
 
 Overall, the evidence that was found in the review of literature suggested that there was 
significant precedent for the cost-effectiveness for pharmacogenomics testing being implemented 
in clinical practice. However, these studies also concluded that further research was needed to 
provide conclusive evidence for the recommended scope of implementation with 
pharmacogenomics, as well as the extent of the clinical validity and utility that this testing 
provides patients (Berm et al., 2016; Pumpton et al., 2016; Wong et al., 2010). One of the 
distinct areas of clinical utility and promotion of patient outcomes through pharmacogenomics 
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testing in primary care settings was mental health care (Brown, Lorenz, Li, & Dechairo, 2017). 
These findings support this project’s goal of addressing this known barrier of pharmacogenomics 
implementation in clinical practice.  
Conceptual Framework/Model 
 
 The conceptual framework that is utilized for the formation of this project is the Iowa 
Model of Evidence-Based Practice. The Iowa Model stands as a valuable tool to clinicians who 
are seeking to address a clinical problem by providing a framework that can be utilized to answer 
essential questions regarding the necessary components of any project. This model serves as the 
underpinning that continually shapes and refines the theoretical intervention for this clinical 
problem (Iowa Model Collaborative, 2017). In this scholarly project the triggering issue was new 
evidence regarding the use of pharmacogenomics testing in general, but more specifically how 
this testing can and should be implemented in the setting of primary care. This general concept 
was further refined by identifying a subsection of data within the overall scope of 
pharmacogenomics that pertains to the identified barriers that stand in opposition to the 
implementation of this testing within the primary care setting. The clinical question of primary 
care providers’ perspectives and level of knowledge regarding pharmacogenomics testing was 
decided upon as the purpose of this scholarly project.  
 With the utilization of the Iowa Model it was determined that the next step in this process 
was to understand if this chosen topic is a priority within the chosen population of primary care 
providers. It was determined through further literature review that there was significant 
precedence for the importance of this topic both within the primary care setting and to primary 
care providers. Once the subject of this scholarly project was determined to have importance, the 
Iowa Model was followed again in the next step of synthesizing a body of evidence that was in 
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support of the scholarly project’s purpose. This was accomplished with systematic and 
comprehensive literature review and the use of literature evaluation tools to understand the 
quality of the evidence that was being gathered.  
 After it was determined that there was sufficient evidence to support the purpose of the 
scholarly project, the next step that was taken was to design the intervention that was going to be 
delivered to the primary care providers who decided to take part in this project’s work. The Iowa 
Model was again followed systematically in the development of the materials that were 
developed for the intervention and evaluation of potential practice change. Through these 
materials that were developed for this project it was determined that change in practice was 
appropriate and that adoption was readily possible. Once these positive results were obtained 
regarding the purpose of the scholarly project, there were follow-up opportunities identified 
using the project materials to understand how this potential change in practice could be best 
supported and nurtured. The results obtained in the course of this scholarly project will be 
disseminated by potential publication and encouragement for others to validate these results by 
replication studies.  
Summary 
 
  The literature review for this project revealed key findings regarding the evidence that 
exists to support the goals of the project, which is to provide a targeted educational intervention 
to primary care providers that will address areas of deficient knowledge as well as correcting 
incorrect perspectives of pharmacogenomics testing. The literature on this subject demonstrates 
preexisting barriers to successful implementation of pharmacogenomics testing in other settings 
such as deficiency in knowledge base, financial concerns, lack of clinical guidelines for 
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therapeutic changes, and efficacy of testing in preventing adverse clinical outcomes, as well as 
promoting optimal patient care. 
SECTION THREE: METHODOLOGY 
Design 
 
 This project is an evidence-based practice project that is guided by the Iowa Model for 
Evidence-Based Practice. The design of this project is quasi-experimental, which will guide the 
outcomes of interest in how they pertain to the clinical phenomenon of interest. This project 
builds upon the foundation of evidence that has been established in the literature regarding the 
use of pharmacogenomics testing as a means of regular management and evaluation in primary 
care settings. Specifically, this project sought to gain an understanding of the levels of 
knowledge in primary care providers regarding the use of pharmacogenomics testing as well as 
their perspectives on this type of testing. It has been noted in other settings that deficient 
knowledge base and perceptions of clinical validity, clinical utility, cost-effectiveness, and lack 
of clinical guidelines serve as significant barriers to the implementation of pharmacogenomics 
testing. These variables were evaluated in the population of chosen primary care providers to 
understand if there was variance or consistency with what is represented in the literature. A 
chosen group of primary care providers in the state of Virginia were surveyed regarding these 
variables of interest. The results were compared against what is represented in the literature and a 
targeted educational intervention was curated and delivered to those that provided responses to 
the original survey. A post-survey was then administered to determine potential changes in 
knowledge base or perceptions, as well as likelihood to include pharmacogenomics testing as a 
result of the intervention.  
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Measurable Outcomes 
 
 Measurable outcomes for this project include positive change in primary care provider 
behavior regarding the likelihood of ordering pharmacogenomics testing for patients seeking 
care, positive comparative change in knowledge base or understanding of pharmacogenomics 
testing and its application in the clinical setting, and positive comparative change in the 
perceptions of pharmacogenomics testing.  
Setting 
 
 This project was not carried out in any one specified organization. The project materials 
were distributed to primary care providers that were identified as having the ability to order PGx 
testing and act on its results. The project considers nurse practitioners (NP), physician assistants 
(PA), and medical doctors (MD) to all meet the criteria of being primary care providers.  The 
goals of advancing care outcomes for primary care patients through the implementation of PGx 
testing was found to be generally recognized as being aligned with the various disciplines of 
providers included for this project. The primary care providers were all located within the state 
of Virginia and were verified to be in active practice at various primary care practices throughout 
the state. Support for the project and its aims were evaluated through voluntary participation in 
the project. 
Population 
   
As stated in the previous section, the participants that were included in this project were 
those that were verified to be primary care providers that were in active practice in the state of 
Virginia. Primary care providers were determined to be any provider that had the practice 
authority and ability to order PGx testing for their patients. Thus, NPs, PAs, and MDs were all 
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included in the project population. The rationale for this chosen population is to identify those 
who have the ability to order this testing for their patients within the primary care setting, 
identify their individual and collective perspectives on PGx testing, and determine if these 
perspectives change with the application of an educational intervention that adequately describes 
the basic nature of PGx testing and its applications towards providing better outcomes for 
patients. Exclusion criteria for this project consisted of either not meeting the determined 
qualifications for being considered a primary care provider or primary care providers that are not 
in current practice. The selection process for this project consisted of the primary researcher 
identifying potential candidates for inclusion in the project and sending information regarding 
this scholarly project via e-mail to the potential participants’ work emails that were obtained via 
primary care listings and websites. The project sample is one that is purposive in methodology, 
as there were criteria that were required for participation, but this was not randomized in nature.   
There were 21 participants included in this project. There are several descriptive features 
about this project’s population that will be detailed here. The large majority of the project’s 
participants were under the age of 45 with 38.1% reporting to be within the age range of 25-34 
years and 38.1% within the age range of 35-44 years. The majority of participants reported to be 
MDs (47%), which was followed by PAs (33%) and then NPs (20%). The majority of those 
surveyed reported that their level of experience in their current role was 1-10 years (76%). The 
participants also reported a slight majority of females (57%) versus males (43%).  
 
Ethical Considerations 
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 This project is intended to be constructed to protect the privacy and responses of all 
chosen subjects. Research ethics training was completed to ensure the protection of privacy and 
security of potentially sensitive information obtained from the subjects through the use of survey. 
The electronic communications to the individuals selected for participation in this project 
included a formal informed consent document, information regarding consent being given by 
means of participation, details regarding the use of the data that would be collected, and the 
measures that would be taken to keep this information secured and private. University IRB 
approval was obtained and it was determined that further organizational IRB approval for each 
participant was unnecessary due to the low-risk nature of this project. This was determined 
through approval from both the scholarly Chair and university IRB representatives.  
Data Collection 
 
 The method of data collection for this project was accomplished through electronic 
communications from the researcher to the intended individuals who met the criteria set forth for 
inclusion regarding their participation in the project. Project participants were contacted directly 
by the primary researcher with a request for their participation through completion of project 
materials. Each participant was provided information regarding the project, its aims, and URL 
links to complete the project materials. Data were then aggregated utilizing a surveying service.    
Tools 
 
 There have been tools utilized to understand the barriers to implementation of 
pharmacogenomics testing, but there are several variables of interest and factors that exist within 
the intended context of study that require the development of a new tool to adequately determine 
the variables of interest as well as their relationship with the context and the subject of 
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pharmacogenomics testing in primary care. The project’s pre survey, educational intervention, 
and post survey were all constructed by the primary researcher. Evidence found within the 
literature served as the conceptual foundation for the tools that were utilized within the project. 
However, many of the tools that were found within the literature specifically dealt with providers 
who already had some modest level of exposure to the concepts of PGx testing, which was not 
the case within this project. Therefore, all of the identified tools within the literature were not 
useful for appropriated implementation within this project.  
Intervention 
 
 This scholarly project began with the identification of this phenomenon of interest. PGx 
testing was initially evaluated in a generalized manner, but was subsequently considered in light 
of its potential application within the context of primary care management. This refined 
phenomenon of interest was investigated further and it was determined that the lack of PGx 
testing within primary care settings is in itself a subject that had been researched by others 
previously. With this foundational literature being present, it was determined that this project’s 
aim was to progress the study of this phenomenon by development of materials that both 
identified primary care providers’ perspectives towards PGx testing and attempted to improve 
these perspectives for the purposes of improved implementation of this testing within the 
primary care setting.  
 Once this baseline for the project was established a comprehensive literature review was 
accomplished. After the aims, goals, and structure of the project were established, the primary 
researcher obtained university IRB approval for carrying out the project in the chosen population 
of primary care providers. Potential participants were contacted by the primary researcher via e-
mail and were voluntarily enrolled in the project. Once participants had completed all project 
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materials the primary researcher gathered and aggregated the responses that the participants had 
provided in both the project pre-survey and post-survey. These data were then analyzed through 
the use of statistical tools to determine significance and meaningful conclusions were then 
drawn.  
Timeline.  The literature review for this project was concluded on June 7, 2019. 
University IRB approval was obtained on September 18, 2019. Implementation of the project 
was carried out from November 15, 2019 through March 4, 2020. Data analysis was completed 
on April 20, 2020. 
 Feasibility Analysis. The anticipated feasibility of this project is high. The costs 
associated with carrying out this project include the use of proprietary survey tools to distribute 
the pre-survey and post-survey, along with included collection methods and data analysis.    
Data Analysis 
Measurable Outcome 1. The first measurable outcome of interest that was evaluated in 
this project was the presence and significance of deficits in knowledge regarding PGx testing as 
a barrier for implementation of this testing.  
Measurable Outcome 2. The second measurable outcome of interest that was evaluated 
in this project was the likelihood of pursuing further education about PGx testing based on 
participation, as well as the methods by which this would be best accomplished according to the 
surveyed population. 
Measurable Outcome 3. The third measurable outcome of interest that was evaluated in 
this project was the significance of the educational intervention on changing the perspectives of 
primary care providers regarding PGx testing. 
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SECTION FOUR:  RESULTS   
Measurable Outcome 1 
 This scholarly project utilized survey tools that were original to this project and were 
created by the primary researcher. These survey tools were shaped and characterized by evidence 
that was found within the literature review; however, there was not a survey tool identified 
within that search that adequately addressed the variables that have been established in the 
survey tools that were utilized in this scholarly project. There were two surveys developed for 
this scholarly project. It was the aim of the pre survey to gather baseline information on the level 
of knowledge and experience that the surveyed providers had with pharmacogenomics testing. 
Beyond this aim it was also determined that the pre survey should be designed to ascertain if 
perspectives were present or absent in the surveyed population, which would also help to 
determine how the educational intervention and post-survey were structured in their content and 
questioning. The post survey sought to understand changes in the perspectives and level of 
knowledge in the surveyed providers in comparison to the results that were evaluated on the pre 
survey tool.  
The data gathered from the survey results for this project showed that there was a 
statistically significant relationship between the current level of knowledge reported by the 
participants and main barrier for PGx testing being clinical responsibility associated with this 
testing. This relationship is clarified with knowledge that within the project population, 95% of 
the participants reported having at most, very little experience with PGx testing. On the pre 
survey, where this relationship is being evaluated, the qualification for the response of very little 
experience is that providers had just heard PGx mentioned but have no actual training in the 
concepts of PGx testing. This is reemphasized with it being noted that 95% of surveyed 
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providers stated that they never include PGx testing as part of their management for patients 
currently. The hallmark of the descriptive statistics for the pre-survey in this project was that 
90% of surveyed providers stated that the unfamiliarity with testing was the main barrier to the 
implementation of PGx testing, as well as 90% of surveyed providers also stating that there is no 
application for PGx testing in their practice currently. This overwhelming presence of responses 
that indicate a deficit in knowledge and overall unfamiliarity leads quite reasonably to 95% of 
surveyed providers stating that they are completely uncomfortable interpreting PGx testing 
results based on their current level of knowledge.  
Beyond these descriptive statistics that outline the first measurable outcome are 
inferential statistics that further develop this theme with statistically significant findings that 
further reinforce these preliminary findings. A Kruskal-Wallis H test showed that there was a 
statistically significant difference in participants who found the main barrier for 
pharmacogenomics testing being clinical responsibility between the current knowledge level of 
pharmacogenomics, χ2(2) = 4.2, p = 0.04 with a mean rank score of 10.0 for participants that 
responded no and 17.0 for participants that responded yes. The Mann-Whitney U Test statistic is 
45.0 with a significance value of 0.08, which shows that there is a significant difference between 
the two factors. Another Kruskal-Wallis H test showed that there was a statistically significant 
difference in participants who found the main barrier for pharmacogenomics testing being 
clinical responsibility between the significance of pharmacogenomics testing, χ2(2) = 5.979, p = 
0.014 with a mean rank score of 9.75 for participants that responded no and 18.5 for participants 
that responded yes. The Mann-Whitney U Test statistic is 49.5 with a significance value of 
0.017, which shows that there is a significant difference between the two factors. 
Measurable Outcome 2 
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 The data gathered from surveying this population of primary care providers also outlined 
distinctive trends that bore out interesting themes in relation to the second outcome of 
measurement that has been established. It was noted in the pre-survey portion that given the 
current level of knowledge regarding PGx concepts, only 14% of providers indicated that they 
believe it is not very important to include PGx education in medical education curriculum. This 
is reflected in the responses given regarding what formats are important for increased knowledge 
regarding PGx concepts. To this question only 19% of providers indicated that graduate school, 
meaning medical school, PA programs, and NP programs, were important to furthering 
education on PGx testing. However, in response to this same question, which allowed for 
multiple answers to be selected, 85% of providers indicated that conferences were important to 
gain knowledge, while 90% indicated that continuing education courses were important to 
increasing understanding of PGx testing. Finally, only 5% of surveyed providers indicated in the 
final question of the pre survey that they were not very interested in receiving education on PGx 
testing.  
 Based on the data acquired from the pre-survey there were statistically significant 
relationships drawn between variables of interest. A Kruskal-Wallis H test showed that there was 
a statistically significant difference in participants who found graduate schools as the best format 
for increasing knowledge about pharmacogenomics between the interest regarding 
pharmacogenomics testing education, χ2(2) = 7.508, p = 0.006 with a mean rank score of 9.35 
for participants that responded no and 18.0 for participants that responded yes. The Mann-
Whitney U Test statistic is 72.0 with a significance value of 0.036, which shows that there is a 
significant difference between the two factors. Another Kruskal-Wallis H test showed that there 
was a statistically significant difference in participants who found the Internet as the best format 
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for increasing knowledge about pharmacogenomics between the importance of 
pharmacogenomics education, χ2(2) = 5.007, p = 0.025 with a mean rank score of 9.2 for 
participants that responded no and 15.5 for participants that responded yes. The Mann-Whitney 
U Test statistic is 82.5 with a significance value of 0.019, which shows that there is a significant 
difference between the two factors. A Kendall's tau-b correlation was run to determine the 
relationships between importance of pharmacogenomics education and the interest regarding 
pharmacogenomics testing education, significance of pharmacogenomics testing, and current 
knowledge level of pharmacogenomics amongst the 21 providers. There was a strong, positive 
correlation between importance of pharmacogenomic education and the three comparative 
factors. Interest regarding pharmacogenomics testing education (τb = 0.436, p = .0.028), 
significance of pharmacogenomics testing (τb = 0.536, p = .0.006), and current knowledge level 
of pharmacogenomics (τb = 0.601, p = .0.003) were all statistically significant. These results are 
detailed in Table 1 with the mentioned correlations and statistical significance denoted.  
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Table 1: Kendall's Tau-b correlation testing on pre-survey results 
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It was determined that there was statistically significant evidence in the gathered data 
regarding interest in PGx education as well as which formats were most desirable in 
accomplishing this furthered knowledge. It was found that 86% of surveyed providers indicated 
on the post survey that they were at least somewhat likely to pursue further PGx education as a 
result of participation in the project. It was also noted that 71% of the surveyed providers 
completely agreed that PGx should be included in the preparatory curriculum of those entering 
the medical field or offered as continuing education opportunities for those in the field of 
primary care. The remaining 29% of surveyed providers indicated on the same question that they 
somewhat agreed with this notion as well. However, the importance of further efforts to educate 
primary care providers with more advanced concepts of PGx testing cannot be understated, as 
95% of surveyed providers listed insufficient knowledge base as a barrier to implementation of 
PGx testing. 
Measurable Outcome 3 
 The third and final outcome measurement is defined by the perspectives that were found 
within the surveyed population in the pre-survey and how these perspectives shifted as a result of 
the educational intervention that was delivered to them in the course of the project. It was 
identified on the pre-survey that providers believed that PGx testing did not have much clinical 
significance, with only 10% indicating PGx testing results were somewhat significant to patient 
outcomes while 43% indicated that this had very little significance or no significance at all to 
patient outcomes. It was also identified that 48% of surveyed providers saw the cost of testing as 
a prohibitive factor in the implementation of PGx testing. In response to asking what the main 
barrier was to implementation of PGx testing, 24% of providers chose cost of testing, 24% of 
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providers chose lack of impact on clinical practice, and 52% chose lack of evidence for clinical 
use.  
 A Kruskal-Wallis H test showed that there was a statistically significant difference in the 
main barrier for pharmacogenomics testing being the cost of testing when compared with cost 
being prohibitive for testing, χ2(2) = 5.469, p = 0.019 with a mean rank score of 12.56 for 
participants that responded no and 6.0 for participants that responded yes. The Mann-Whitney U 
Test statistic is 15.0 with a significance value of 0.04, which shows that there is a significant 
difference between the two factors. A Kendall's tau-b correlation was run to determine the 
relationship between interest regarding pharmacogenomics testing education and the significance 
of pharmacogenomics testing and likeliness to pursue pharmacogenomics testing amongst 21 
participants. There was a strong, positive correlation between interest regarding 
pharmacogenomics testing education and the two factors. Significance of pharmacogenomics 
testing (τb = 0.439, p = .0.028), and likeliness to pursue pharmacogenomics testing (τb = 0.592, p 
= .0.003) were both statistically significant.  
 In the post survey data it was clear that there was a distinct change in the answering of 
questions regarding the identified perspectives from the pre survey, with 85% of surveyed 
providers who at least somewhat agreed that the educational intervention thoroughly addressed 
the barriers to implementation of PGx testing. It was also found that at least 90% of the surveyed 
providers at least somewhat agreed that PGx testing has clinical significance in the management 
of primary care, 80% at least somewhat agreed that PGx testing is financially viable in the 
management of primary care patients, and 95% indicating that they at least somewhat agreed that 
PGx testing can greatly reduce adverse drug reactions in patients. When asked who PGx should 
be considered for in a multiple response style question, 95% of surveyed providers indicated that 
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the cases where adverse drug reactions are more likely, and 58% indicated that this should also 
be considered for patients where normal therapies are noted to be ineffective.  
A Kruskal-Wallis H test showed that there was a statistically significant difference in 
participants who planned to pursue pharmacogenomics education due to the project and between 
intervention testing considered normal therapy ineffective, χ2(2) = 4.365, p = 0.037 with a mean 
rank score of 8.0 for participants that responded no and 13.25 for participants that responded yes. 
The Mann-Whitney U Test statistic is 85.0 with a significance value of 0.036, which shows that 
there is a significant difference between the two factors. Another Kruskal-Wallis H test showed 
that there was a statistically significant difference in participants who found pharmacogenomics 
testing significant due to the intervention and between testing considered normal therapies 
ineffective due to the intervention, χ2(2) = 5.47, p = 0.019 with a mean rank score of 7.83 for 
participants that responded no and 13.38 for participants that responded yes. The Mann-Whitney 
U Test statistic is 82.5 with a significance value of 0.019, which shows that there is a significant 
difference between the two factors. A Kendall's tau-b correlation was run to determine the 
relationship between participants who found pharmacogenomics testing to have significance 
because of the intervention and whether pharmacogenomics concepts should be included in 
preparatory curriculum of those entering the medical field amongst 21 participants. There was a 
strong, positive correlation between participants found the intervention addressed barriers and 
whether intervention testing is viable. Whether intervention testing is viable (τb = 0.663, p = 
.0.003) was statistically significant. Kendall's tau-b correlation was run to determine the 
relationship between participants who, due to the intervention, found that pharmacogenomics 
testing can greatly reduce adverse drug reaction events, whether PGx testing is viable, 
participants who stated that they are planning to pursue pharmacogenomics education due to the 
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project, and if the intervention is appropriate for primary care amongst the 21 providers. There 
was a strong, positive correlation between all the three factors. Whether intervention testing is 
viable (τb = 0.436, p = .0.037), participants planning to pursue pharmacogenomics education due 
to the project (τb = 0.509, p = .0.015), and if the intervention is appropriate for primary care (τb 
= 0.529, p = .0.014) were all statistically significant. These results are detailed in Table 2 with 
the mentioned correlations and statistical significance denoted. 
 
Table 2: Kendall's Tau-b correlation testing on post-survey results 
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SECTION FIVE:  DISCUSSION 
Implication for Practice 
 
The findings based on the project’s measurable outcomes contribute to the growing 
knowledge surrounding PGx overall, but more specifically the method by which this advent of 
personalized medicine can and should be implemented in the primary care setting. Previous 
research has focused primarily on evaluating the efforts to implement PGx testing, the 
generalized themes that stand as general barriers to the implementation of this testing, and 
evaluation of the potential benefits of implementing PGx testing in various care settings. In this 
project it was established that in the surveyed population of primary care providers there was an 
overwhelming baseline deficit in knowledge regarding the most basic concepts of what PGx 
testing is, its application, and common misconceptions about  the testing itself. Beyond this, it 
was determined that through exposure to an educational intervention that included the core 
concepts of PGx testing that providers were willing to pursue the inclusion of this testing in their 
practice as well as to engage in further education regarding the subject of PGx testing. As a result 
of the survey responses, this project was also helpful in illuminating the perceived need for 
education about PGx concepts to be included in preparator curriculum and to be offered as 
continuing education opportunities for those in the field of primary care.  
The importance of these findings for both the surveyed providers as well as the patients 
that they manage cannot be understated. As previously mentioned, it was identified that a large 
majority of the surveyed providers indicated that they would be pursuing both continued 
education as well as implementation of PGx testing in the management of their patients. The 
surveyed providers identified that the most applicable use case for this testing would be the 
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avoidance of adverse drug reaction events, which PGx testing results can be leveraged 
advantageously towards this goal.  
 The limitations of this project are found within the severely limited number of providers 
who responded to the invitation and met the requirements of finishing all the project’s materials 
to be included for analysis. The results therefore cannot be generalized to any other context 
outside of the one that has been studied within the confines of this project. There is also the 
possibility for bias in those that did both respond to the invitation for inclusion and completed 
the project’s materials, in that these providers may have been more open to both learning and 
implementing PGx concepts when compared to the general pool of primary care providers. To 
understand this better these results should be compared against those with similar aims that are 
carried out in other primary care provider populations to determine if these results can be 
validated. 
Sustainability 
 
The sustainability in accomplishing change of practice when it comes to implementation 
of PGx testing is high. There is an ever-growing precedent based on many variables for the 
implementation of PGx testing within the field of primary care. It has been shown in this project 
that primary care providers will not implement testing that they do not understand, but if this 
barrier of knowledge deficit can be addressed then it is likely that change in practice is 
forthcoming. Priorities in the field of medicine are closely aligned with the principles of PGx 
testing, which contributes heavily to the sustainability of practice change towards 
implementation of this testing. PGx testing aims to primarily provide better outcomes for every 
single patient who is evaluated and treated within the primary care context. PGx texting 
secondarily aims to provide care that is precise, evidence-based, and cost-effective.  
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Dissemination Plan 
 
  The plan for dissemination of the project’s results occurs through several mechanisms. 
The first mechanism by which dissemination may happen is through the potential and likely 
change in practice that will occur on the individual level in all the providers that took part in this 
project. These providers indicated that as a result of participation in this project their 
perspectives on PGx testing have changed, and that they will likely pursue further PGx testing 
and implement PGx testing as part of their regular management. This change in practice for these 
providers will likely cause colleagues or supervising physicians to take note of these changes and 
evaluate the efficacy of PGx testing just as the surveyed providers have as a result of inclusion in 
this project. The secondary mechanism for the dissemination of these results is for this project to 
be published for those who are interested in the field of PGx testing, for those who wish to know 
how this may affect the management of patients in the primary care setting, and finally for those 
who are interested in pursuing research regarding PGx testing’s impact on clinical practice.  
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Appendix A  
Evidence Table 
Name: Joshua Fleming 
Clinical Question: How does a targeted educational intervention affect the reported level of understanding and perspectives for 
providers in a primary care health system? 
Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Example, A. (2015) Title etc. 
per Current APA 
To identify the need for technology to 
prevent falls 
A convenience 
sample of 44 nurses 
in an acute care 
hospital  
A non-experimental, 
descriptive survey 
Findings indicate that 
fall rates decreased by 
2% with the 
introduction of 
technology into the 
care setting 
Level 6: 
descriptive 
design 
Conducted in 
only one 
setting, small 
sample size 
Does provide some 
good foundational 
information even 
though the level is a 
6.  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Relling, M.V., & Evans, 
W.E. (2015). 
Pharmacogenomics in the 
clinic. Nature, 526(7573), 
343 
 
To provide background information 
regarding the growing field of 
pharmacogenomic testing and its efficacy 
in clinical practice.  
Literature review of 
related and relevant 
literature regarding 
this subject. 
No details regarding 
processes by which 
literature was 
obtained are 
mentioned in the 
article.  
Authors conclude that 
there is a growing 
body of knowledge 
regarding 
pharmacogenomics 
testing, which is 
greatly impacted by 
the advent of the 
human genome project 
and increased 
understanding 
regarding the subject 
of genetics in general. 
Discussed here is the 
potential level of 
impact that discoveries 
regarding 
pharmacogenes can 
have on the change in 
treatment methods and 
patient outcomes.  
Level 6: 
Descriptive 
design 
The study falls 
short in not 
providing 
specific 
recommendatio
ns for further 
work to be 
done in order 
to move the 
field of study 
forward.  
Yes. This study 
provides 
significant 
general insights 
into the subject of 
pharmacogenomi
cs testing as well 
as the barriers to 
further 
implementation 
of this in clinical 
practice.  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Rosenman, M.B., Decker, 
B., Levy, K.D., Holmes, 
A.M., Pratt, V.M., & Eadon, 
M.T. (2017). Lessons 
learned when introducing 
pharmacogenomic panel 
testing into clinical practice. 
Value in Health, 20(1), 54-
59.  
This study describes the challenges and 
potential solutions to implementation 
projects of pharmacogenomics testing 
being provided. 
A diverse population 
(patients who often 
have multiple chronic 
illnesses, in a large 
urban safety-net 
hospital and its 
outpatient clinics). 
The study was 
conducted as a 
descriptive case 
study of the 
implementation of a 
pharmacogenomics 
program with wide 
scope (14 genes, 43 
variants, and 27 
medications).  
The study identified 
several areas of 
challenges that were 
developed through 
observation and 
evaluation of the 
implementation 
process in this care 
environment that 
included both extrinsic 
factors, patient-
mediated factors, and 
provider-mediated 
factors. 
Level 6: 
Descriptive 
design 
The problem of 
cost for testing 
is addressed by 
means of 
correlation 
with the rise of 
other 
interventions 
that have been 
promised as 
revolutionary 
in theory yet 
complex and 
inconclusive in 
practice. This 
may be helpful 
in predicting 
the complex 
implementation 
process of 
pharmacogeno
mics testing in 
primary care, 
but this 
relationship is 
not proven to 
be concrete or 
predictive of 
the future of 
pharmacogeno
mics testing. 
Yes. The information 
gleaned through 
experiencing multi-
faceted variables that 
serve as potentially 
significant barriers 
against 
implementation 
efforts proves to pave 
the road forward for 
further investigation 
and intervention to 
address these issues 
effectively.  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Just, K.S., Steffens, M., 
Swen, J.J., Patrinos, G.P., 
Guchelaar, H.J., & Stingl, 
J.C. (2017). Medical 
education in 
pharmacogenomics—results 
from a survey on 
pharmacogenetic knowledge 
in healthcare professionals 
within the European 
pharmacogenomics clinical 
implementation project 
Ubiquitous 
Pharmacogenomics (U-
PGx). European Journal of 
Clinical Pharmacology, 
73(10), 1247-1252. 
To evaluate the attitudes, experience 
with, and education on pharmacogenomic 
testing in medical providers who are 
expected to be the leaders of this new 
change towards the future where this 
testing is part of regular evaluation and 
management of patients.  
The sample group 
was comprised of 70 
individuals that was a 
combination of 
physicians and 
pharmacists.  
The authors 
developed a 
questionnaire 
including 29 
questions. It was 
spread out to 
healthcare 
professionals 
working at the 
future 
implementation 
sites (in Austria, 
Greece, Italy, 
Netherlands, 
Slovenia, Spain and 
Great Britain) of the 
U-PGx project in 
preparation of an 
educational 
programme. Aim of 
the survey was to 
analyse the current 
educational 
situation at the 
implementation 
sites. 
 
The results showed 
that even though a vast 
majority of the 
respondents (more 
than 84%) showed that 
pharmacogenomics 
was relevant to their 
current practice it was 
still not prevalent as 
more than 65% of 
respondents had not 
ordered or 
recommended testing 
in the last year.  
Level 6: 
Descriptive 
design 
The study 
showcased a 
significant 
barrier to the 
implementation 
of 
pharmacogeno
mics testing in 
clinical 
practice as 
being a lack of 
knowledge and 
specific 
education 
regarding the 
interpretation 
of testing 
results, but this 
study fails to 
propose any 
meaningful 
intervention 
based on these 
findings.  
Yes. The evidence 
presented in this 
study is crucial to 
understand as part of 
further research into 
the education that is 
necessary for 
physicians in existing 
practice as well as the 
potential for 
integration of 
changes to the 
curriculum of 
medical students who 
are going to be the 
most affected by 
these potential 
changes in the future.  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Plumpton, C. O., Roberts, 
D., Pirmohamed, M., & 
Hughes, D. A. (2016). A 
systematic review of 
economic evaluations of 
pharmacogenetic testing for 
prevention of adverse drug 
reactions. PharmacoEconom
ics, 34(8), 771-793.  
 
This study is aimed at the cost-
effectiveness evaluation of 
pharmacogenomic testing through 
systematic review of literature to prevent 
adverse drug reactions in patients that are 
about to be placed on medications that 
can be heavily affected by genetic 
factors. 
47 of a total of 852 
articles met inclusion 
criteria for 
independent review 
of both abstract and 
full text. 
The systematic 
review protocol was 
registered with 
PROSPERO, the 
international 
database of 
prospectively 
registered 
systematic reviews 
(identification 
number 
CRD42014013673), 
conducted 
according to the 
Centre for Reviews 
and Dissemination’s 
guidance for 
undertaking reviews 
in healthcare.  
 
There was evidence 
supporting the cost 
effectiveness of testing 
for HLA-B*57:01 
(prior to abacavir), 
HLA-B*15:02 and 
HLA-A*31:01 (prior 
to carbamazepine), 
HLA-B*58:01 (prior 
to allopurinol) and 
CYP2C19 (prior to 
clopidogrel treatment). 
Economic evidence 
was inconclusive with 
respect to TPMT 
(prior to 6-
mercaptoputine, 
azathioprine and 
cisplatin therapy), 
CYP2C9 and 
VKORC1 (to inform 
genotype-guided 
dosing of coumarin 
derivatives), MTHFR 
(prior to methotrexate 
treatment) and factor 
V Leiden testing (prior 
to oral contraception). 
Testing for A1555G is 
not cost effective 
before prescribing 
aminoglycosides. 
 
Level 1: 
Systematic 
Review 
While the 
study’s results 
were shown to 
have 
conclusive 
findings 
regarding the 
cost-
effectiveness in 
providing 
pharmacogeno
mic testing in 
for some 
medications, 
there are still 
those that 
require further 
investigation 
because of 
inconclusive or 
mixed results. 
Yes. This systematic 
review evaluates the 
cost-effectiveness for 
pharmacogenomics 
based on reduction in 
adverse drug side 
effects. With the 
financial implications 
of 
pharmacogenomics 
testing it is necessary 
to understand how 
this testing will 
provide economic 
advantages to both 
patients, insurance 
providers, and health 
systems overall 
which support the 
successful 
implementation of 
this testing in the 
future.  
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Berm, E. J. J., de Looff, M., 
Wilffert, B., Boersma, C., 
Annemans, L., Vegter, S., & 
Postma, M. J. (2016). 
Economic evaluations of 
pharmacogenetic and 
pharmacogenomic screening 
tests: A systematic review. 
second update of the 
literature. PLoS One, 11(1)  
 
To evaluate the literature on the 
economic implications of 
pharmacogenomics screening tests to 
help determine if this testing is cost 
effective. 
80 articles were 
found to meet 
inclusion criteria of 
the initial 733 articles 
that were found 
regarding the subject 
matter.  
A literature search 
was performed in 
PubMed and papers 
published between 
August 2010 and 
September 2014, 
investigating the 
cost-effectiveness of 
PGx screening tests, 
were included. 
Papers from 2000 
until July 2010 were 
included via two 
previous systematic 
reviews. Studies’ 
overall quality was 
assessed with the 
Quality of Health 
Economic Studies 
(QHES) instrument. 
The literature review 
found that testing was 
mostly a cost-effective 
or cost-saving 
intervention across the 
studies that were 
accumulated and 
evaluated.  
Level 1: 
Systematic 
Review 
It is difficult to 
provide 
conclusive and 
concrete 
economic 
evaluations 
that are 
established as a 
standard 
because of 
several 
different 
variables such 
as lack of hard 
clinical 
evidence 
regarding the 
pharmacogeno
mics testing’s 
utility in the 
clinical setting, 
variability in 
compliance in 
physicians who 
are ordering 
the testing and 
not changing 
management 
based off of 
recommendatio
ns, and the 
variability in 
price of 
pharmacogeno
mics testing 
between 
different 
geographical 
environments.  
Yes. This systematic 
review contains a 
robust foundation for 
the validity of 
pharmacogenomics 
testing as part of 
regular screening and 
management from the 
perspective of 
economic 
implications, which 
is a large concern 
surrounding this field 
in the literature.  
Kirchheiner, J., Fuhr, U., & 
Brockmöller, J. (2005). 
Pharmacogenetics-based 
therapeutic 
recommendations -- ready 
for clinical practice? Nature 
The study discusses different variations 
and factors that affect or inhibit the use 
and application of pharmacogenomics 
testing in real-world clinical 
environments  
The study is a 
literature review that 
does not have 
definable search 
terms or 
The article does not 
contain specific 
parameters for the 
methods by which 
the evidence was 
Based on the articles 
reviewed by the 
authors, it was found 
that there are several 
limitations to the field 
of pharmacogenomics 
Level 6: 
Descriptive 
design 
The study 
notes these 
polymorphisms 
being detected 
in patients, but 
fails to 
Yes. This review 
describes several 
different case studies 
where there have 
been, in some cases, 
significant adverse 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Reviews. Drug 
Discovery, 4(8), 639-647.  
 
inclusion/exclusion 
criteria listed 
compiled or 
proposed 
that limit its 
implementation and 
application in clinical 
practice 
substantiate 
how these 
findings will be 
repeated in 
large-scale 
studies or the 
implications to 
clinical 
practice based 
on the results 
of those 
hypothetical 
studies 
effects that have been 
noted in patients with 
known 
polymorphisms  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Wong, W. B., Carlson, J. J., 
Thariani, R., & Veenstra, D. 
L. (2010). Cost effectiveness 
of 
pharmacogenomics. Pharma
coEconomics, 28(11), 1001-
1013.  
 
To provide a foundational understanding 
regarding the economics of 
pharmacogenomics testing through 
systematic review of literature that 
discusses these points 
34 articles were 
included in the 
review of literature 
from an original 54 
articles that were 
selected based off of 
other reviews of 
literature and new 
evidence  
A literature search 
was performed 
during October 
2009 using the 
following publically 
available databases: 
PubMed, UK 
National Institute 
for Health and 
Clinical Excellence 
(NICE).Tufts CEA 
registry and 
Canadian Agency 
on Drugs and 
Technology in 
Health (CADTH). 
We employed a 
literature search 
strategy similar to a 
previous CEA of 
PGx reviews, which 
involved starting 
with broad search 
terms, then 
narrowing down to 
specific Medical 
Subject Heading 
(MeSH) terms, 
followed by disease-
specific searches 
and expert 
recommendations. 
 
The studies that were 
surveyed and 
evaluated found that 
there were many 
biogenetic markers 
that had clinical 
significance, but only 
two that possessed 
clinical significance as 
well as clinical utility 
based on the economic 
benefits that these may 
possess for the patient 
populations that can be 
served by them 
Level 1: 
Systematic 
Review 
There are 
limitations in 
the current 
base of 
evidence on 
how the results 
of the studies 
that were 
included in this 
review have on 
clinical 
practice based 
on insufficient 
evidence and 
inconclusive 
results  
Yes. There is 
supporting evidence, 
though not 
conclusive, to 
support the cost-
effectiveness of 
pharmacogenomics 
testing having a place 
in regular clinical 
practice 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Phillips, K.A., Veenstra, 
D.L., Oren, E., Lee, J.K., 
Sadee, W. (2001). Potential 
role of pharmacogenomics in 
reducing adverse drug 
reactions: a systematic 
review. Journal of the 
American Medical 
Association, 286(14), 2270-
2279. 
To evaluate the potential role of 
pharmacogenomics in reducing the 
incidence of adverse drug reactions 
 
Detailed inclusion 
criteria were used to 
select studies. 18 of 
333 adverse drug 
reaction studies and 
22 of 61 variant allele 
review articles were 
included in the final 
review 
 
MEDLINE English-
language only 
searches for adverse 
drug reaction 
studies published 
between January 
1995 and June 2000 
and review articles 
of variant alleles of 
drug-metabolizing 
enzymes published 
between January 
1997 and August 
2000.  
 
Results suggest that 
drug therapy based on 
individuals' genetic 
makeups may result in 
a clinically important 
reduction in adverse 
outcomes 
 
Level 1: 
Systematic 
Review 
The 
information 
included here, 
while being a 
solid 
foundation for 
further study 
and potential 
implications to 
clinical 
practice, it is 
old evidence in 
a subject that is 
constantly 
evolving into 
greater scopes 
and practices 
Yes. Even though the 
evidence may be old 
the information here 
should be referenced 
in continual work 
towards further 
research and greater 
applications in 
clinical practice 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Adams, S. M., Anderson, K. 
B., Coons, James C, Smith, 
R. B., Meyer, S. M., Parker, 
L. S., & Empey, Philip, E. 
(2016). Advancing 
pharmacogenomics 
education in the core 
PharmD curriculum through 
student personal genomic 
testing. American Journal of 
Pharmaceutical 
Education, 80(1), 1-11. 
 
To evaluate the impact of personal 
genetic testing on the educational benefits 
for pharmD students learning these 
concepts as part of curriculum 
Study consisted 110 
PharmD students and 
10 faculty members 
Study involved pre- 
and post-survey 
tools to evaluate for 
changes in 
perception and level 
of understanding 
that was proposed to 
be affected or 
changed by the 
implementation of 
this new type of 
curriculum  
It was found that 
students who 
underwent genetic 
testing were found to 
have significant 
advantages in 
understanding and 
manipulation of 
curriculum materials 
when compared with 
students who did not 
take part in the 
intervention  
Level 3: 
Quasi-
Experiment
al Design 
The study is 
limited by its 
poor discussion 
surrounding 
the areas of 
difference in 
outcomes that 
were achieved 
by the students 
who were 
participants in 
the genetic 
testing as 
compared to 
students who 
did not take 
part in this 
Yes. The study 
provides insight into 
novel concepts 
regarding the 
education of future 
clinicians who are 
expected to have 
robust understanding 
regarding genetic 
testing and 
implications on 
clinical practice to 
achieve higher buy-in 
from these 
individuals and, in-
turn, provide better 
outcomes for 
adherence to testing 
as well as better 
understanding. 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Ferreri, S.P., Greco, A.J., 
Michaels, N.M., O’Connor, 
S.K., Chater, R.W., Viera, 
A.J., Faruki, H., McLeod, 
H.L., & Roederer, M.W. 
(2014). Implementation of a 
pharmacogenomics in a 
community pharmacy, 
Journal of the American 
Pharmacists Association, 
54(2), 172-180. 
To determine the feasibility of 
implementing a pharmacogenomics 
service in a community pharmacy 
 
18 patients taking 
clopidogrel, a drug 
metabolized by 
CYP2C19. 
 
A retrospective data 
abstraction of 
prescription fills 
between the dates of 
May 1, 2011, and 
October 26, 2011, 
yielded 53 patients 
with at least one fill 
of clopidogrel. 
Since this was a 
feasibility project, 
any patient with a 
prescription for 
clopidogrel was 
included. A final 
sample of 18 were 
determined based on 
other 
inclusion/exclusion 
criteria 
 
A pharmacogenomics 
service can be an 
extension of 
medication therapy 
management services 
in a community 
pharmacy. Prescribers 
are receptive to having 
community 
pharmacists conduct 
pharmacogenomics 
testing, but 
reimbursement is a 
challenge. 
 
Level 4: 
Correlation
al Design 
The study did 
not adequately 
explain why 
the insurance 
agencies in 
these cases 
were reluctant 
towards 
reimbursement 
or how this 
difficulty can 
be overcome in 
future studies 
or work 
towards 
clinical 
practice.  
Yes. This study 
demonstrates 
practical application 
of 
pharmacogenomics 
testing being carried 
out on a drug with 
known significant 
side effects for 
persons with genetic 
abnormalities and 
proposes how the 
relationship with 
pharmacists carrying 
out this testing can 
work in the care-team 
environment with 
suggestions made 
towards the 
prescribers based on 
the results that are 
examined in these 
patients  
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Benitwez, J., Jablonski, 
M.R., Allen, J.D., & Winner, 
J.G. (2015). The clinical 
validity and utility of 
combinatorial 
pharmacogenomics: 
Enhancing patient outcomes. 
Applied and Translational 
Genomics, 5(1), 47-49. 
This study evaluates the differences 
measured in clinical validity, utility, and 
economic benefit to the patient between 
single gene evaluations and 
combinatorial pharmacogenomics panels 
that are designed to evaluate multiple 
genes in an individual that is receiving 
psychiatric pharmacotherapies  
The study evaluates 
three studies done on 
the clinical validity, 
three studies on the 
clinical utility, and an 
undisclosed amount 
of clinical research 
on the economic 
impact of 
combinatorial 
pharmacogenomics 
testing panels for 
patients receiving 
psychiatric 
pharmacotherapies 
The methods by 
which this evidence 
is compiled or 
evaluated is not 
disclosed in the 
contents of the 
article 
The authors concluded 
based on the amassed 
clinical research that 
the use of 
combinatorial 
pharmacogenomics 
testing panels showed 
a significant efficacy 
in all three defined 
domains of interest, 
thus showing 
preference for this 
type of testing for 
better outcomes as 
well as further 
implications for the 
field in evaluating 
these results on a 
larger scale 
Level 6: 
Descriptive 
Design 
The study’s 
limitations 
surround the 
small amount 
of evidence in 
previous 
studies that 
support the 
purported 
conclusion, and 
highlights the 
need for further 
research and 
replication of 
findings that 
are listed here 
for increased 
basis on 
change in 
clinical 
practice 
Yes. The study 
provides preliminary 
evidence that suggest 
promising benefits in 
three variables of 
pharmacogenomics 
testing that are often 
listed as barriers 
towards greater 
implementation and 
effective change in 
practice 
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Brown, L.C., Lorenz, R.A., 
Li, J., & Dechairo, B.M. 
(2017). Economic utility: 
Combinatorial 
pharmacogenomics and 
medication cost savings for 
mental health care in a 
primary care setting. Clinical 
Therapeutics, 39(3). 
The primary objective of this study was 
to determine potential cost savings of 
combinatorial PGx testing over the 
course of 1 year in patients with mental 
illness treated by primary care providers 
(PCPs) and psychiatrists who had 
switched or added a new psychiatric 
medication after patients failed to 
respond to monotherapy. 
 
Of the 2168 patients, 
1662 were taking 
eligible GeneSight 
panel medications 
365 days after the 
combinatorial PGx 
test date and were 
included in this sub-
analysis.  
 
This study was a 
sub-analysis of a 1-
year, prospective 
trial comparing 
medication costs of 
2168 patients 
undergoing 
GeneSight testing. 
Pharmacy claims 
were provided by a 
pharmacy benefits 
manager, comparing 
medication costs 6 
months before 
combinatorial PGx 
testing and followed 
up for 1 year after 
the testing. This 
analysis compared 
congruence and cost 
savings per patient 
based on the type 
of health care 
provider administeri
ng care. 
 
PCPs congruent with 
combinatorial PGx 
testing provided the 
most medication cost 
savings for payers and 
patients at $3988 per 
member per year 
 
Level 4: 
Correlation
al Design 
The study 
failed to 
explain in 
detail the 
potential for 
lack of 
congruence in 
pharmacogeno
mics testing 
between PCPs 
and 
psychiatrists or 
explicitly 
explain points 
of benefit for 
PCPs being the 
primary source 
of 
pharmacogeno
mics testing as 
it was found 
that there was 
greater cost 
savings for the 
patients 
because the 
PCP was able 
to not only 
follow the 
psychiatric 
recommendatio
n results from 
the testing but 
also the non-
psychiatric 
recommendatio
ns that the 
testing brought 
as part of the 
combinatorial 
panel  
Yes. The study 
supports the 
economic advantage 
in providing 
pharmacogenomics 
testing with an 
emphasis that this 
testing should take 
place in the PCP 
setting to provide the 
best economic impact 
for the patients 
seeking care 
Romagnoli, K.M., Boyce, 
R.D., Empey, P.E., Adams, 
S., & Hochheiser, H. (2016). 
Bringing clinical 
The authors of the article sought to 
understand the pharmacogenomics 
information needs and resource 
requirements of pharmacists as these are 
The study included 
14 pharmacists 
located in 6 different 
clinical environments 
The authors 
conducted 
qualitative inquiries 
and used the results 
Responses suggest that 
pharmacists anticipate 
an imminently 
growing role for 
Level 6: 
Descriptive 
Design 
The study does 
not provide 
explicit 
statistical data 
Yes. This study 
shows the 
perspectives of 
several pharmacists 
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etc. (Current APA 
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Demographics, 
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Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
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Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
pharmacogenomics 
information to pharmacists: 
A qualitative study of 
information needs and 
resource requirements, 
International Journal of 
Medical Informatics, 86, 54-
61. 
 
key participants in the decision-making 
regarding pharmacotherapies in the 
clinical setting 
 
of those inquiries to 
develop a model of 
pharmacists’ 
pharmacogenomics 
information needs 
and resource 
requirements. 
 
pharmacogenomics in 
their practice. 
Participants value 
information from trust-
worthy resources like 
FDA product labels, 
but found that this 
information was 
difficult to accurately 
and efficiently 
approach 
 
or evidence 
that notes the 
need for 
increased 
knowledge and 
inclusion in 
pharmacogeno
mics testing 
beyond stating 
that this field is 
likely to need 
the clinical 
knowledge of 
pharmacists for 
better patient 
outcomes 
on the subject of 
pharmacogenomics 
and the need for 
increased knowledge 
and prevalence of 
succinct and useful 
clinical resources for 
the utilization by 
providers to better 
provide meaningful 
clinical decisions 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
St Stauver, J.L., Bielinski, 
S.J., Olson, J.E., Bell, E.J., 
McGree, M.E., Jacobson, 
D.J., McCormick, J.B., 
Caraballo, P.J., Takahashi, 
P.Y., Roger, V.L. & Vitek, 
C.R. (2016). Integrating 
pharmacogenomics into 
clinical practice: Promise vs 
reality, American Journal of 
Medicine, 129(10), 1093-
1099. 
To evaluate PCPs’ response to clinical 
support systems that are aimed towards 
providing better patient outcomes by 
notifying the provider that a change is 
recommended based on the patient’s 
pharmacogenomics profile  
159 primary care 
physicians in the 
Mayo Clinic 
network. Of this 
original sample there 
were only 90 
respondants 
Mayo Clinic 
primary care 
practice were sent e-
mail surveys to 
understand their 
perspectives on the 
implementation and 
use of 
pharmacogenomic 
testing in their 
clinical practice. 
Surveys assessed 
how the clinicians 
felt about 
pharmacogenomics 
and whether they 
thought electronic 
pharmacogenomics 
clinical decision 
support alerts were 
useful.  
 
Our results indicate 
that clinicians are not 
comfortable with the 
integration of 
pharmacogenomic 
data into their clinical 
practice. Because most 
patients expect that 
their 
pharmacogenomic 
data will help guide 
their care decisions, 
further efforts to 
educate clinicians 
about the utility of 
pharmacogenomic 
data for clinical 
practice, and efforts to 
refine PGx-CDS alerts 
to make them useful 
and user-friendly, may 
close the gap between 
the clinician's 
approach and patient 
expectations 
 
Level 4: 
Correlation
al Design  
The limited 
response rate 
of 57% limits 
the efficacy of 
the data that is 
pulled from 
this specific 
population and 
does not 
account for 
individual 
physicians who 
are outliers 
with either 
negative or 
positive bias 
based on 
personal 
experience 
with the 
clinical 
decision 
support tools 
Yes. This study 
features potentially 
helpful insights into 
better integration of 
pharmacogenomics 
testing clinical 
decision support 
systems in future care 
settings that reflects 
positive physician 
interactions and 
better outcomes with 
adherence to change 
in practice based on 
recommendations 
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Article Title, Author, 
etc. (Current APA 
Format) 
Study Purpose Sample 
(Characteristics of 
the Sample: 
Demographics, 
etc.) 
Methods Study Results Level of 
Evidence (Use 
Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? (Yes or 
No) Provide 
Rationale. 
Olson, J. E., Rohrer Vitek, 
C. R., Bell, E. J., Mcgree, M. 
E., Jacobson, D. J., St 
Sauver, J. L., Bielinski, S. J. 
(2017). Participant-perceived 
understanding and 
perspectives on 
pharmacogenomics: The 
mayo clinic RIGHT protocol 
(right drug, right dose, right 
time). Genetics in 
Medicine, 19(7), 819-825.  
 
The purpose of this study was to identify 
variables included in educational 
resources that are provided to patients 
undergoing pharmacogenomics testing 
that predict understanding as well as how 
to further refine these materials based on 
responses from those surveyed 
A total of 1010 
patients were chosen 
based off of inclusion 
and exclusion criteria 
and of these patients 
there were 869 
respondants 
The participants 
were mailed their 
individual 
pharmacogenomics 
test results along 
with educational 
materials and a 
survey to complete 
regarding their 
understanding of the 
presented materials 
and potential for 
this information to 
improve medication 
adherence 
Even with increased 
efforts paid towards 
simplifying patient 
education regarding 
the results of 
pharmacogenomics 
testing it was found 
that more than a third 
of the surveyed 
patients did not 
understand the results 
Level 4: 
Correlation
al Design 
The limitations 
of this study 
include the 
potential for 
these findings 
to be 
generalized 
given specific 
characteristic 
of the surveyed 
population 
such as patients 
who have a 
higher level of 
education 
when 
compared to 
other samples 
or a higher 
likelihood in 
response rates 
because of bias 
factors that 
may be specific 
to this 
population 
Yes. This study 
highlights the 
necessity of 
providing patients 
with the information 
that they need in a 
format that is not 
confusing or using 
terms that are 
difficult for lay 
people to understand. 
This paves the way 
for further refinement 
of educational 
materials which can 
have significantly 
positive impact on 
the clinical benefits 
of 
pharmacogenomics 
testing in patients 
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Appendix D 
 This project took place outside of any formal organizational structure, which excludes this requirement of documented 
organizational approval. This decision was corroborated with the researcher’s chair and Liberty University IRB personnel. Both of 
these entities agreed that given the low risk status of this project’s aims that forgoing organizational approval for surveyed providers 
was unnecessary.  
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Appendix E 
 
 
 
Pharmacogenomics Pre-survey Questions 
1. What is your current level of knowledge on pharmacogenomics testing? 
a. Never heard of it  
b. Very little experience (Heard of it mentioned) 
c. Limited understanding (Received any amount of formal training) 
d. Solidified understanding (Feeling confident in simple concepts surrounding testing) 
e. Advanced understanding (Received extensive education on concepts of testing)  
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2. How often is pharmacogenomics testing part of your management currently? 
a. Never 
b. Sometimes (Less than 10 cases in a year) 
c. Often (Less than 50 cases in a year) 
d. Frequently (More than 50 cases in a year) 
e. Every day 
3. In your current practice, what is drug dosing primarily based on? (Select all that apply) 
a. Renal function 
b. Hepatic function 
c. Age 
d. Weight 
e. Sex 
f. Comorbid conditions 
g. Clinical guidelines 
h. Personal preference and familiarity 
i. Biomarkers from pharmacogenomics testing 
4. How clinically significant do you believe pharmacogenomics testing results are to patient outcomes? 
a. No significance at all 
b. Very little significance 
c. Neutral 
d. Somewhat significant 
e. Very significant 
5. Do you see the cost of testing as a prohibitive factor in implementing pharmacogenomics testing? 
a. In all cases 
b. In most cases 
c. Neutral  
d. In some cases 
e. In no cases 
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6. What is the main barrier for the implementation of pharmacogenomics testing in your current management of patients? (Select 
all that apply) 
a. Unfamiliarity with testing 
b. Cost of testing 
c. Lack of evidence for clinical use 
d. Lack of impact on clinical practice 
e. Clinical responsibility for testing results 
7. What do you believe is the best application of pharmacogenomics testing in your current practice? 
a. Preventative management 
b. Polypharmacy concerns 
c. Ineffectiveness of conventional therapies 
d. Complex patient presentation and needs 
e. No application at all  
f. As part of regular management 
8. How comfortable are you with interpreting pharmacogenomics testing results based on your current level of knowledge? 
a. Completely uncomfortable 
b. Somewhat uncomfortable 
c. Neutral 
d. Comfortable 
e. Very comfortable 
9. How important do you believe it is to include pharmacogenomics education in medical education curriculum? 
a. Not important at all  
b. Not very important  
c. Neutral 
d. Somewhat important 
e. Very important 
10. What formats do you believe are important for increased knowledge surrounding pharmacogenomics testing? 
a. Conferences 
b. Continuing education courses 
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c. College 
d. Graduate school (Medical school, PharmD school, PA school, NP school) 
e. Internet-based education modules 
11. What is your age? 
a. < 25 years old 
b. 25-34 years old 
c. 35-45 years old  
d. 45-55 years old 
e. > 55 years old 
12. What is your discipline? 
a. Medical Doctor 
b. Physician Assistant 
c. Nurse Practitioner 
d. Doctor of Osteopathic Medicine 
e. Pharmacist 
13. How many years of experience do you have in your current role? 
a. 1-3 years of experience 
b. 4-6 years of experience 
c. 7-10 years of experience 
d. 11-15 years of experience 
e. 16-21 years of experience 
f. 22-30 years of experience  
g. > 30 years of experience 
14. What is your gender? 
a. Male 
b. Female 
15. How interested are you to receive education regarding pharmacogenomics testing? 
a. Not interested at all 
b. Not very interested 
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c. Neutral 
d. Interested 
e. Very interested 
Pharmacogenomics Post-survey Questions 
1. How likely are you to pursue including pharmacogenomics testing in your clinical management of patients as a result of the 
information provided in the educational intervention? 
a. No likelihood 
b. Not likely 
c. Neutral 
d. Somewhat likely 
e. Very likely 
2. What factors are still present that stand as barriers to implementation of testing? (Select all that apply) 
a. Lack of foreseeable clinical impact 
b. Cost of testing 
c. Insufficient knowledge base 
d. Clinical responsibility for testing 
e. Not knowing when and who to test 
3. How likely are you to pursue further pharmacogenomics education as a result of your participation in this project? 
a. No likelihood 
b. Not likely 
c. Neutral 
d. Somewhat likely 
e. Very likely 
4. The educational intervention in this project thoroughly addressed the barriers to implementation of pharmacogenomics testing. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral  
d. Somewhat agree  
PHARMACOGENOMICS IN PRIMARY CARE: BARRIERS TO IMPLEMENTATION  65 
 
e. Completely agree 
5. Based on the project’s educational intervention, pharmacogenomics testing has clinical significance in the management of 
primary care patients. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral 
d. Somewhat agree 
e. Completely agree 
6. Based on the project’s educational intervention, pharmacogenomics testing is financially viable in the management of primary 
care patients. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral 
d. Somewhat agree 
e. Completely agree 
7. Based on the project’s educational intervention, pharmacogenomics concepts should be included in the preparatory curriculum 
of those entering the medical field or offered as continuing education opportunities for the field of primary care. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral 
d. Somewhat agree 
e. Completely agree 
8. Based on the project’s educational intervention, pharmacogenomics testing is most appropriately accomplished for patients 
within the primary care setting. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral 
d. Somewhat agree 
e. Completely agree 
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9. Based on the project’s educational intervention, pharmacogenomics testing implementation can greatly reduce adverse drug 
reaction events. 
a. Completely disagree 
b. Somewhat disagree 
c. Neutral 
d. Somewhat agree 
e. Completely agree 
10. Based on the project’s educational intervention, pharmacogenomics testing should be considered for (Select all that apply): 
a. No primary care patients 
b. In cases where adverse drug reactions are more likely 
c. In cases where polypharmacy is a concern 
d. In patients where normal therapies are noted to be ineffective 
e. In all primary care patients  
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Appendix F 
CONSENT FORM 
Pharmacogenomics Testing in Primary Care: Barriers to Implementation 
Joshua Fleming 
Liberty University 
School of Nursing 
 
You are invited to be in a research study on how the current perspectives and level of understanding pertaining to the use of 
pharmacogenomics testing in primary care settings are affected by targeted educational intervention. You were selected as a possible 
participant because of the setting in which you work, the capability that you possess in potentially ordering pharmacogenomics testing, 
specific perspectives and level of understanding that you may possess as it relates to the subject of pharmacogenomics in the primary 
care setting, and availability for participation in educational intervention and post-surveying. You were also selected based on your 
role in the primary care setting as either a physician, nurse practitioner, or physician assistant. Please read this form and ask any 
questions you may have before agreeing to be in the study. 
 
Joshua Fleming, a doctoral candidate in the School of Nursing at Liberty University, is conducting this study.  
 
Background Information: The purpose of this study is aimed towards understanding the level of understanding and perspectives of 
primary care providers, which include physicians, nurse practitioners, and physician assistants, on the subject of pharmacogenomics 
testing. Specifically, the outcome being measured through this study is the level of impact that a targeted educational intervention has 
on the level of understanding and perspectives of primary care providers. This will be evaluated through establishing baseline results 
through pre-surveying and comparing this to the results that are evaluated through post-surveying after the targeted educational 
intervention regarding pharmacogenomics is delivered.  
 
Procedures: If you agree to be in this study, I would ask you to do the following things: 
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1. Provide an accurate and unbiased baseline regarding current level of understanding and perspectives of pharmacogenomics in 
the primary care setting. This will be established through the answering of questions in the pre-survey that will be delivered 
electronically to your organizational email. It is asked that you answer all survey questions completely within two weeks of 
initial dispersal.   
2. Be willing to receive targeted educational intervention on the subject of pharmacogenomics testing that will be developed to 
address barriers that have been noted in the literature as well as those that are identified to be prevalent among respondents, 
based on pre-surveying results.  
3. Provide an accurate and unbiased report regarding post-education level of understanding and perspectives of 
pharmacogenomics testing in the primary care setting. This will be established through the answering of questions in the post-
survey that will be delivered electronically to your organizational email. It is asked that you answer all survey questions 
completely within four weeks of initial dispersal of post-survey, which will coincide with dispersal of targeted educational 
intervention. 
 
Risks: The risks involved in this study are minimal, which means they are equal to the risks you would encounter in everyday life. 
 
Benefits: The direct benefits participants should expect to receive from taking part in this study are gains in knowledge base regarding 
the potential application of pharmacogenomics testing in the primary care setting, which contains many potential benefits for both 
patients receiving care as well as providers who are managing these patients’ care. Benefits to society include the possible increasing 
acceptance of pharmacogenomics testing in the primary care setting, and subsequent possible prevalence of this testing in regular care 
and management, which stand to benefit patients seeking care in the primary care setting through affecting many different patient 
outcomes positively. 
 
Compensation: Participants will not be compensated for participating in this study.  
 
Confidentiality: The records of this study will be kept private. In any sort of report I might publish, I will not include any information 
that will make it possible to identify a subject. Research records will be stored securely, and only the researcher will have access to the 
records. Data will be stored on a password locked computer and may be used in future presentations. After three years, all electronic 
records will be deleted. 
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Voluntary Nature of the Study: Participation in this study is voluntary. Your decision whether or not to participate will not affect 
your current or future relations with Liberty University. If you decide to participate, you are free to not answer any question or 
withdraw at any time. 
 
How to Withdraw from the Study: If you choose to withdraw from the study, please inform the researcher that you wish to 
discontinue your participation prior to submitting your study materials. Your responses will not be recorded or included in the study. 
 
Contacts and Questions: The researcher conducting this study is Joshua Fleming. You may ask any questions you have now. If you 
have questions later, you are encouraged to contact him at (919)-810-5427 / jmfleming2@liberty.edu. You may also contact the 
researcher’s faculty chair, Ken Thompson, at kthompson55@liberty.edu.  
 
If you have any questions or concerns regarding this study and would like to talk to someone other than the researcher[s], you are 
encouraged to contact the Institutional Review Board, 1971 University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email 
at irb@liberty.edu.   
 
Please notify the researcher if you would like a copy of this information for your records. 
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Statement of Consent: I have read and understood the above information. I have asked questions and have received answers. I 
consent to participate in the study.  
 
 
______________________________________________________________________________ 
Signature of Participant        Date 
 
 
______________________________________________________________________________ 
Signature of Investigator        Date 
(Liberty University, 2019) 
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